G. Poncet-Montange - Concepedia

Author

G. Poncet-Montange

Centre National de la Recherche Scientifique ORCID

Also Known As

G. Labesse, G. Poncet-Montange, Guillaume Poncet-Montange

Publications

446

Citations

H-Index

Concepts

All Affiliations

Centre National de la Recherche Scientifique Inserm The University of Texas MD Anderson Cancer Center Université de Montpellier University of California, San Francisco

About

G. Poncet-Montange is an author at Centre National de la Recherche Scientifique specializing in medicine, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	319
2	Natural Sciences	7	7	345
3	Cell Biology	4	4	245
4	Biochemistry	3	3	68
5	Biomolecular Engineering	1	1	36

G. Poncet-Montange

Publications

437

Citations

H-Index

Page 1

	Year	Citations
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor Wylie S. Palmer, G. Poncet-Montange, Gang Liu, Journal of Medicinal Chemistry Combinatorial ChemistryEpigenetic ChangeX-ray Cocrystal StructuresMolecular BiologyChemical Biology	2015	152
The Human Orphan Nuclear Receptor Tailless (TLX, NR2E1) Is Druggable Cindy Benod, Rosa Villagomez, Carly S. Filgueira, PLoS ONE Drug TargetMolecular BiologyPharmacotherapyPotent LigandsTumor Biology	2014	53
NAD Kinases Use Substrate-assisted Catalysis for Specific Recognition of NAD G. Poncet-Montange, Liliane Assairi, Stefan T. Arold, Journal of Biological Chemistry	2007	41
Prion Protein—Antibody Complexes Characterized by Chromatography-Coupled Small-Angle X-Ray Scattering Lester Carter, Seung Joong Kim, Dina Schneidman‐Duhovny, Biophysical Journal Protein AssemblyNatural SciencesMolecular BiologyChromatography-coupled Small-angle X-rayPrion Disease	2015	36
Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2 G. Poncet-Montange, Yanai Zhan, Jennifer Bardenhagen, Biochemical Journal Epigenetic ChangeMolecular BiologyEpigeneticsBromodomain Flexibility RevealsMolecular Recognition	2014	36
A Survey of Antiprion Compounds Reveals the Prevalence of Non-PrP Molecular Targets G. Poncet-Montange, Susan S. Martin, Olga V. Bogatova, Journal of Biological Chemistry Pharmaceutical ScienceDrug TargetPharmacotherapyChemical BiologyDrug Resistance	2011	30
Screening and In Situ Synthesis Using Crystals of a NAD Kinase Lead to a Potent Antistaphylococcal Compound Muriel Gelin, G. Poncet-Montange, Liliane Assairi, Structure Nad Kinase LeadBioorganic ChemistryBiochemistryNatural SciencesMedicine	2012	24
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models Ulrike Rauh, Wei Guo, Michael H. Serrano‐Wu, Nature Cancer	2024	23
Oligomeric-Induced Activity by Thienyl Pyrimidine Compounds Traps Prion Infectivity Adeline Ayrolles-Torro, Thibaut Imberdis, Joan Torrent, Journal of Neuroscience	2011	18
Lack of dynamics in the MabA active site kills the enzyme activity: practical consequences for drug-design studies G. Poncet-Montange, Stéphanie Ducasse-Cabanot, Gilles Labesse, Acta Crystallographica Section D Biological Crystallography Drug TargetProtein AssemblyMolecular BiologyProtein FoldingMaba Active Site	2007	14

Page 1